
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/623987/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. Molecular Psychiatry, 2018, 23, 1261-1269.	4.1	522
2	Accelerated Gray and White Matter Deterioration With Age in Schizophrenia. American Journal of Psychiatry, 2017, 174, 286-295.	4.0	168
3	Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics, 2019, 20, 37-47.	0.6	126
4	Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry,the, 2016, 3, 585-590.	3.7	110
5	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	1.7	107
6	Towards the integration of pharmacogenetics in psychiatry. Current Opinion in Psychiatry, 2019, 32, 7-15.	3.1	103
7	Kava in the Treatment of Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology, 2013, 33, 643-648.	0.7	99
8	Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: Convergent pathway analysis findings from two independent samples. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 494-502.	1.1	97
9	Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia. American Journal of Psychiatry, 2019, 176, 552-563.	4.0	97
10	Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry, 2021, 54, 5-17.	1.7	96
11	White Matter Disruptions in Schizophrenia Are Spatially Widespread and Topologically Converge on Brain Network Hubs. Schizophrenia Bulletin, 2017, 43, sbw100.	2.3	85
12	Predictors of substance use among homeless youth in San Diego. Addictive Behaviors, 2005, 30, 1100-1110.	1.7	84
13	Kava for the Treatment of Generalized Anxiety Disorder RCT: Analysis of Adverse Reactions, Liver Function, Addiction, and Sexual Effects. Phytotherapy Research, 2013, 27, 1723-1728.	2.8	81
14	Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics Journal, 2018, 18, 613-622.	0.9	80
15	Individual deviations from normative models of brain structure in a large cross-sectional schizophrenia cohort. Molecular Psychiatry, 2021, 26, 3512-3523.	4.1	78
16	Systematic review and critical appraisal of child abuse measurement instruments. Psychiatry Research, 2019, 272, 106-113.	1.7	73
17	Genetic association studies of methamphetamine use disorders: A systematic review and synthesis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 1025-1049.	1.1	70
18	Neuregulin-1 and schizophrenia in the genome-wide association study era. Neuroscience and Biobehavioral Reviews, 2016, 68, 387-409.	2.9	68

#	Article	IF	CITATIONS
19	ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Translational Psychiatry, 2012, 2, e198-e198.	2.4	61
20	The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes. NPJ Schizophrenia, 2015, 1, 15043.	2.0	60
21	Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. BMC Psychiatry, 2017, 17, 60.	1.1	59
22	Early origins of mental disorder - risk factors in the perinatal and infant period. BMC Psychiatry, 2016, 16, 270.	1.1	57
23	Systematic evaluation of commercial pharmacogenetic testing in psychiatry. Pharmacogenetics and Genomics, 2017, 27, 387-393.	0.7	56
24	Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug and Alcohol Dependence, 2007, 90, 159-165.	1.6	54
25	Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1336-1341.	1.1	54
26	Investigation of peripheral complement factors across stages of psychosis. Schizophrenia Research, 2019, 204, 30-37.	1.1	50
27	Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. Translational Psychiatry, 2017, 7, e1196-e1196.	2.4	49
28	Negative mood and sexual behavior among non-monogamous men who have sex with men in the context of methamphetamine and HIV. Journal of Affective Disorders, 2009, 119, 84-91.	2.0	46
29	Effects of oxytocin and genetic variants on brain and behaviour: Implications for treatment in schizophrenia Research, 2015, 168, 614-627.	1.1	44
30	Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive Abilities. Schizophrenia Bulletin, 2018, 44, 560-574.	2.3	44
31	The Influence of Maternal Parenting Style on the Neural Correlates of Emotion Processing in Children. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 274-282.	0.3	44
32	Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study (Supplementry Table). Current Pharmacogenomics and Personalized Medicine, 2009, 7, 164-188.	0.2	44
33	The ubiquitin proteasome system and schizophrenia. Lancet Psychiatry,the, 2020, 7, 528-537.	3.7	43
34	Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. Journal of Affective Disorders, 2019, 245, 1007-1015.	2.0	42
35	Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Pharmacogenomics Journal, 2020, 20, 192-201.	0.9	41
36	Antidepressant pharmacogenetics. Current Opinion in Psychiatry, 2014, 27, 43-51.	3.1	40

3

#	Article	IF	CITATIONS
37	Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 595-607.	1.8	40
38	Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: Preliminary findings. Journal of the International Neuropsychological Society, 2010, 16, 890-901.	1.2	39
39	Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection. Clinical Pharmacology and Therapeutics, 2019, 106, 309-312.	2.3	38
40	Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Human Psychopharmacology, 2013, 28, 516-522.	0.7	36
41	Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Frontiers in Cellular Neuroscience, 2013, 7, 95.	1.8	36
42	Functional brain networks in treatment-resistant schizophrenia. Schizophrenia Research, 2017, 184, 73-81.	1.1	36
43	Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. Journal of NeuroVirology, 2011, 17, 239-247.	1.0	35
44	Insula Functional Connectivity in Schizophrenia: Subregions, Gradients, and Symptoms. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 399-408.	1.1	35
45	Meta-analysis reveals associations between genetic variation in the 5′ and 3′ regions of Neuregulin-1 and schizophrenia. Translational Psychiatry, 2017, 7, e1004-e1004.	2.4	32
46	Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Canadian Journal of Psychiatry, 2020, 65, 521-530.	0.9	32
47	Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis. Translational Psychiatry, 2013, 3, e251-e251.	2.4	31
48	Elevated ubiquitinated proteins in brain and blood of individuals with schizophrenia. Scientific Reports, 2019, 9, 2307.	1.6	31
49	The Impact of Childhood Adversity on Cognitive Development in Schizophrenia. Schizophrenia Bulletin, 2020, 46, 140-153.	2.3	31
50	Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. Trials, 2015, 16, 493.	0.7	29
51	Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial,. European Neuropsychopharmacology, 2018, 28, 1126-1136.	0.3	29
52	Antidepressant pharmacogenetics in children and young adults: A systematic review. Journal of Affective Disorders, 2019, 254, 98-108.	2.0	27
53	The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placeboâ€controlled, doubleâ€blind study. Human Psychopharmacology, 2012, 27, 262-269.	0.7	26
54	Exploring Heterogeneity on the Wisconsin Card Sorting Test in Schizophrenia Spectrum Disorders: A Cluster Analytical Investigation. Journal of the International Neuropsychological Society, 2019, 25, 750-760.	1.2	26

#	Article	IF	CITATIONS
55	Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 660-664.	0.3	26
56	Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients. Translational Psychiatry, 2017, 7, 1280.	2.4	25
57	Moving pharmacoepigenetics tools for depression toward clinical use. Journal of Affective Disorders, 2019, 249, 336-346.	2.0	25
58	Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. Translational Psychiatry, 2020, 10, 37.	2.4	24
59	COMTVal158Met Polymorphism, Executive Dysfunction, and Sexual Risk Behavior in the Context of HIV Infection and Methamphetamine Dependence. Interdisciplinary Perspectives on Infectious Diseases, 2010, 2010, 1-9.	0.6	23
60	Predictors of depression and anxiety symptom trajectories in the 24 months following diagnosis of breast or gynaecologic cancer. Breast, 2016, 26, 100-105.	0.9	23
61	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clinical Pharmacology and Therapeutics, 2020, 107, 50-52.	2.3	22
62	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 921-932.	1.8	22
63	Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Australian and New Zealand Journal of Psychiatry, 2020, 54, 288-297.	1.3	22
64	Sequence2Script: A Web-Based Tool for Translation of Pharmacogenetic Data Into Evidence-Based Prescribing Recommendations. Frontiers in Pharmacology, 2021, 12, 636650.	1.6	22
65	Correlation of major depressive disorder symptoms with FKBP5 but not FKBP4 expression in human immunodeficiency virus–infected individuals. Journal of NeuroVirology, 2010, 16, 399-404.	1.0	21
66	Escitalopram Efficacy in Depression. Journal of Clinical Psychopharmacology, 2014, 34, 645-648.	0.7	21
67	Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations. Translational Psychiatry, 2017, 7, e1037-e1037.	2.4	21
68	Interrogating the Evolutionary Paradox of Schizophrenia: A Novel Framework and Evidence Supporting Recent Negative Selection of Schizophrenia Risk Alleles. Frontiers in Genetics, 2019, 10, 389.	1.1	21
69	The role of depression pharmacogenetic decision support tools in shared decision making. Journal of Neural Transmission, 2019, 126, 87-94.	1.4	21
70	Methylenetetrahydrofolate reductase (<i>MTHFR</i>) genetic variation and major depressive disorder prognosis: A fiveâ€year prospective cohort study of primary care attendees. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 68-76.	1.1	20
71	Peripheral Transcription of NRG-ErbB Pathway Genes Are Upregulated in Treatment-Resistant Schizophrenia. Frontiers in Psychiatry, 2017, 8, 225.	1.3	20
72	The schizophrenia genetics knowledgebase: a comprehensive update of findings from candidate gene studies. Translational Psychiatry, 2019, 9, 205.	2.4	19

#	Article	IF	CITATIONS
73	Parenting × Brain Development interactions as predictors of adolescent depressive symptoms and well-being: Differential susceptibility or diathesis-stress?. Development and Psychopathology, 2020, 32, 139-150.	1.4	19
74	EPA and DHA as markers of nutraceutical treatment response in major depressive disorder. European Journal of Nutrition, 2020, 59, 2439-2447.	1.8	19
75	S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. Psychopharmacology, 2020, 237, 209-218.	1.5	19
76	Preliminary evidence of ethnic divergence in associations of putative genetic variants for methamphetamine dependence. Psychiatry Research, 2010, 178, 295-298.	1.7	18
77	Intensive residential treatment for obsessive-compulsive disorder: Outcomes and predictors of patient adherence to cognitive-behavioural therapy. Journal of Obsessive-Compulsive and Related Disorders, 2016, 9, 82-89.	0.7	18
78	Pharmacogenetic Decision Support Tools: A New Paradigm for Late-Life Depression?. American Journal of Geriatric Psychiatry, 2018, 26, 125-133.	0.6	18
79	Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. American Journal of Geriatric Psychiatry, 2020, 28, 609-629.	0.6	18
80	Hippocampal subfields and visuospatial associative memory across stages of schizophrenia-spectrum disorder. Psychological Medicine, 2019, 49, 2452-2462.	2.7	17
81	Alphaâ€5 and â€3 nicotinic receptor gene variants predict nicotine dependence but not cessation: Findings from the COMMIT cohort. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 227-235.	1.1	16
82	Effects of COMT, DRD2, BDNF, and APOE Genotypic Variation on Treatment Efficacy and Cognitive Side Effects of Electroconvulsive Therapy. Journal of ECT, 2015, 31, 129-135.	0.3	16
83	Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life. Pharmacogenomics, 2018, 19, 1269-1284.	0.6	16
84	Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines?. Pharmacopsychiatry, 2020, 53, 174-178.	1.7	16
85	Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 2021, 11, 1334.	1.1	16
86	Impact of COMT Val158Met on executive functioning in the context of HIV and methamphetamine. Neurobehavioral HIV Medicine, 2010, 2010, 1.	2.0	15
87	An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. Advances in Integrative Medicine, 2015, 2, 49-55.	0.4	15
88	Erythrocyte polyunsaturated fatty acid composition is associated with depression and FADS genotype in Caucasians. Nutritional Neuroscience, 2018, 21, 589-601.	1.5	15
89	Risk and resilience brain networks in treatment-resistant schizophrenia. Schizophrenia Research, 2018, 193, 284-292.	1.1	15
90	<i>CYP2D6</i> and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 33-45.	0.7	15

#	Article	IF	CITATIONS
91	Brain morphology is differentially impacted by peripheral cytokines in schizophrenia-spectrum disorder. Brain, Behavior, and Immunity, 2021, 95, 299-309.	2.0	15
92	Homelessness and Neuropsychological Impairment. Journal of Nervous and Mental Disease, 2010, 198, 790-794.	0.5	14
93	Characteristics of Homeless Youth Attending Two Different Youth Drop-In Centers. Youth and Society, 2011, 43, 28-43.	1.3	14
94	Negative Symptoms of Psychosis Correlate with Gene Expression of the Wnt/β-Catenin Signaling Pathway in Peripheral Blood. Psychiatry Journal, 2013, 2013, 1-4.	0.7	14
95	Blood and brain protein levels of ubiquitin-conjugating enzyme E2K (UBE2K) are elevated in individuals with schizophrenia. Journal of Psychiatric Research, 2019, 113, 51-57.	1.5	14
96	Psychomotor depressive symptoms may differentially respond to venlafaxine. International Clinical Psychopharmacology, 2013, 28, 121-126.	0.9	13
97	The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia. Psychiatry Research - Neuroimaging, 2015, 234, 182-187.	0.9	13
98	Schizophrenia genetics in the genome-wide era: a review of Japanese studies. NPJ Schizophrenia, 2017, 3, 27.	2.0	13
99	Mind the prevalence rate: overestimating the clinical utility of psychiatric diagnostic classifiers. Psychological Medicine, 2018, 48, 1225-1227.	2.7	13
100	Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. Molecular Psychiatry, 2022, 27, 593-605.	4.1	13
101	Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment. International Clinical Psychopharmacology, 2016, 31, 127-133.	0.9	12
102	Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder. Pharmacogenetics and Genomics, 2017, 27, 1-6.	0.7	12
103	Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disorders. Psychological Medicine, 2020, 50, 1475-1489.	2.7	12
104	Successful Clozapine Rechallenge After Suspected Clozapine-Associated Myocarditis. Journal of Clinical Psychopharmacology, 2021, 41, 218-220.	0.7	12
105	Formative Assessment of ARM-U: A Modular Intervention for Decreasing Risk Behaviors Among HIV-Positive and HIV-Negative Methamphetamine-Using MSM. Open AIDS Journal, 2010, 4, 105-115.	0.1	12
106	Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review. Psychiatry Research, 2021, 305, 114247.	1.7	12
107	Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders. Translational Psychiatry, 2022, 12, 145.	2.4	12
108	Chronic Illness Histories of Adults Entering Treatment for Coâ€occurring Substance Abuse and Other Mental Health Disorders. American Journal on Addictions, 2012, 21, 1-4.	1.3	11

#	Article	IF	CITATIONS
109	Downregulation of plasma SELENBP1 protein in patients with recent-onset schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85, 1-6.	2.5	11
110	Predictors of Weapon Carrying in Youth Attending Drop-in Centers. American Journal of Health Behavior, 2009, 33, 745-58.	0.6	10
111	Typologies of positive psychotic symptoms in methamphetamine dependence. American Journal on Addictions, 2015, 24, 94-97.	1.3	10
112	Antidepressant Pharmacogenetics. American Journal of Psychiatry, 2017, 174, 417-418.	4.0	10
113	Neuregulin-1 (<i>NRG1</i>) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia. Psychological Medicine, 2018, 48, 801-809.	2.7	10
114	Exploring the moderating effects of dopaminergic polymorphisms and childhood adversity on brain morphology in schizophrenia-spectrum disorders. Psychiatry Research - Neuroimaging, 2018, 281, 61-68.	0.9	10
115	An Interleukin-1 beta (IL1B) haplotype linked with psychosis transition is associated with IL1B gene expression and brain structure. Schizophrenia Research, 2019, 204, 201-205.	1.1	10
116	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1295-1305.	1.3	10
117	Pharmacogenetic Tests in Psychiatry. American Journal of Psychiatry, 2018, 175, 189-189.	4.0	9
118	High impact child abuse may predict risk of elevated suicidality during antidepressant initiation. Australian and New Zealand Journal of Psychiatry, 2013, 47, 1191-1195.	1.3	8
119	Effects of neuregulinâ€1 genetic variation and depression symptom severity on longitudinal patterns of psychotic symptoms in primary care attendees. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 62-67.	1.1	8
120	The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Moderates the Effects of Childhood Abuse on Severity of Depressive Symptoms in a Time-Dependent Manner. Frontiers in Psychiatry, 2016, 7, 151.	1.3	8
121	Interaction between hypothalamic-pituitary-adrenal axis genetic variation and maternal behavior in the prediction of amygdala connectivity in children. NeuroImage, 2019, 197, 493-501.	2.1	8
122	Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients. Pharmacogenetics and Genomics, 2020, 30, 145-152.	0.7	8
123	Identification of high-impact gene–drug pairs for pharmacogenetic testing in Alberta, Canada. Pharmacogenetics and Genomics, 2021, 31, 29-39.	0.7	8
124	"Black box―pharmacogenetic decision-support tools in psychiatry. Revista Brasileira De Psiquiatria, 2020, 42, 113-115.	0.9	8
125	Towards pharmacogenetic-based treatment in psychiatry. Journal of Neural Transmission, 2019, 126, 1-3.	1.4	7
126	Adverse effect of catechol-O-methyltransferase (COMT) Val158Met met/met genotype in methamphetamine-related executive dysfunction. Addictive Behaviors, 2019, 98, 106023	1.7	7

#	Article	IF	CITATIONS
127	CYP2D6 testing to guide risperidone and aripiprazole therapy. Lancet Psychiatry,the, 2019, 6, 362-364.	3.7	7
128	Breast Cancer Survivor Symptoms: A Comparison of Physicians' Consultation Records and Nurse-Led Survivorship Care Plans. Clinical Journal of Oncology Nursing, 2020, 24, E34-E42.	0.3	7
129	The impact of smoking status on cognition and brain morphology in schizophrenia spectrum disorders. Psychological Medicine, 2022, 52, 3097-3115.	2.7	7
130	Preliminary evidence of motor impairment among polysubstance 3,4-methylenedioxymethamphetamine users with intact neuropsychological functioning. Journal of the International Neuropsychological Society, 2010, 16, 1047-1055.	1.2	6
131	Polygenic phenotypic plasticity moderates the effects of severe childhood abuse on depressive symptom severity in adulthood: A 5-year prospective cohort study. World Journal of Biological Psychiatry, 2017, 18, 75-81.	1.3	6
132	Genetic variation in cytokine genes and risk for transition to psychosis among individuals at ultra-high risk. Schizophrenia Research, 2018, 195, 589-590.	1.1	6
133	Assessment of Placental Cortisol Pathway Gene Expression in Term Pregnant Women with Anxiety. Neuropsychobiology, 2019, 77, 1-7.	0.9	6
134	Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia. Journal of Neural Transmission, 2019, 126, 19-25.	1.4	6
135	Impact of CYP2C19 genotype-predicted enzyme activity on hippocampal volume, anxiety, and depression. Psychiatry Research, 2020, 288, 112984.	1.7	6
136	Methamphetamine-Associated Psychosis: A Model for Biomarker Discovery in Schizophrenia. , 2011, , 327-343.		6
137	Effects of Persisting Emotional Impact from Child Abuse and Norepinephrine Transporter Genetic Variation on Antidepressant Efficacy in Major Depression: A Pilot Study. Clinical Psychopharmacology and Neuroscience, 2015, 13, 53-61.	0.9	5
138	Serotonin transporter polymorphism (<i>5HTTLPR</i>), severe childhood abuse and depressive symptom trajectories in adulthood. BJPsych Open, 2015, 1, 104-109.	0.3	5
139	Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based Care. JAMA Psychiatry, 2018, 75, 1090.	6.0	5
140	Systematic Review and Meta-Analysis of L-Methylfolate Augmentation in Depressive Disorders. Pharmacopsychiatry, 2022, 55, 139-147.	1.7	5
141	N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 117, 110550.	2.5	5
142	Oestrogen Alpha-Receptor Variant and Two-Year Memory Decline in Midlife Australian Women. Neuropsychobiology, 2012, 66, 259-265.	0.9	4
143	Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV. Journal of NeuroVirology, 2015, 21, 535-543.	1.0	4
144	Decreased peripheral TNF alpha (TNF-α) mRNA expression in patients with treatment-resistant schizophrenia. Schizophrenia Research, 2018, 202, 387-388.	1.1	4

#	Article	IF	CITATIONS
145	Treatment of Refractory Obsessive-Compulsive Disorder with Nutraceuticals (TRON): A 20-week, open label pilot study. CNS Spectrums, 2021, , 1-35.	0.7	4
146	Encountering Pharmacogenetic Test Results in the Psychiatric Clinic. Canadian Journal of Psychiatry, 2022, 67, 95-100.	0.9	4
147	The effects of a muscarinic receptor 1 gene variant on cortical thickness and surface area in schizophrenia. Psychiatry Research - Neuroimaging, 2018, 280, 62-64.	0.9	3
148	Beneficial effects of natural products on female sexual dysfunction: A systematic review and meta-analysis. Phytomedicine, 2021, 93, 153760.	2.3	3
149	Disruptions in white matter microstructure associated with impaired visual associative memory in schizophrenia-spectrum illness. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 971-983.	1.8	3
150	Perspectives on the Clinical Use of Pharmacogenetic Testing in Late-Life Mental Healthcare: A Survey of the American Association of Geriatric Psychiatry Membership. American Journal of Geriatric Psychiatry, 2022, 30, 560-571.	0.6	3
151	Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic. , 2022, 1, .		3
152	Assessing Neuropsychological Performance in a Migrant Farm Working Colonia in Baja California, Mexico: A Feasibility Study. Journal of Immigrant and Minority Health, 2011, 13, 742-747.	0.8	2
153	G-protein β3 subunit genetic variation moderates five-year depressive symptom trajectories of primary care attendees. Journal of Affective Disorders, 2014, 165, 64-68.	2.0	2
154	Estimating the Potential Impact of CYP2C19 and CYP2D6 Genetic Testing on Protocol-Based Care for Depression in Canada and the United States. Molecular Neuropsychiatry, 2019, 5, 27-33.	3.0	2
155	The effects of a muscarinic receptor 1 gene variant on executive and non-executive cognition in schizophrenia spectrum disorders. Psychiatry Research, 2019, 273, 178-180.	1.7	2
156	Engaging in building the educational support needed to deliver precision health in Canada. Healthcare Management Forum, 2020, 33, 135-139.	0.6	2
157	Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: A pharmacovigilance database study. Psychiatry Research, 2020, 290, 113048.	1.7	2
158	Formidable Challenges in the Search for Biomarkers of Psychiatric Disorders. Metabolomics: Open Access, 2011, 01, .	0.1	2
159	Consumer participation in personalized psychiatry. , 2020, , 63-68.		1
160	Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram. Pharmacogenetics and Genomics, 2021, 31, 172-176.	0.7	1
161	Psychotropic prescribing rates and pharmacogenomic testing implications for autism in the Canadian primary care sentinel surveillance network. Pharmacogenetics and Genomics, 2022, 32, 94-100.	0.7	1
162	Whole-genome sequencing analysis of clozapine-induced myocarditis. Pharmacogenomics Journal, 2022, 22, 173-179.	0.9	1

#	Article	IF	CITATIONS
163	Dispensing patterns of mental health medications before and during the COVID-19 pandemic in Alberta, Canada: An interrupted time series analysis. International Journal of Psychiatry in Medicine, 2022, , 009121742210848.	0.8	1
164	Exploration of a genomic expression and pathway analysis approach to neurocognitive performance: preliminary findings. Neurobehavioral HIV Medicine, 2010, , 23.	2.0	0
165	SimPEL: Simulationâ€based power estimation for sequencing studies of lowâ€prevalence conditions. Genetic Epidemiology, 2018, 42, 480-487.	0.6	0
166	Reply to Searcy and colleagues. Pharmacogenetics and Genomics, 2018, 28, 108-109.	0.7	0
167	Pharmacoepigenetics of Major Depression. , 2019, , 747-754.		0
168	Opportunities and challenges of implementation models of pharmacogenomics in clinical practice. , 2020, , 449-457.		0
169	Genetic testing in psychiatry: State of the evidence. , 2020, , 437-448.		0
170	Reply to Dawes et al Canadian Journal of Psychiatry, 2020, 65, 586-587.	0.9	0
171	Editorial: Pharmacogenomics: From Bench to Bedside and Back Again. Frontiers in Genetics, 2022, 13, 878191.	1.1	0
172	Pharmacogenetic Testing Knowledge and Attitudes among Pediatric Psychiatrists and Pediatricians in Alberta, Canada Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2022, 31, 18-27.	0.7	0